
CDSCO Panel Approves Novartis Healthcare's Protocol Amendment to study Iptacopan
New Delhi: The Subject Expert Committee (SEC), functional under the Central Drug Standard Control Organization (CDSCO), has approved the protocol amendment proposal presented by Novartis Healthcare for Iptacopan (LNP023) study. This came after the firm …